Good morning. Here is my BioBusiness update for the week. This focuses on the business side of biotech and medical devices. Who raised what. Who bought who. Senior appointments and more.
➡ Patient Square Capital aims to roll up NanoString assets with $220M bid
➡ Astellas puts the cork back in $350M Xork deal with Cartesian
➡ Tubulis rides wave of ADC interest to $138M financing round
➡ Spruce lays off 5th of staff in wake of phase 2 hyperplasia fail
➡ J&J’s Reed takes home $20M-plus payday in his first year
➡ Sanofi to shut down UK R&D site, displacing 90 staffers
➡ Novartis hits the cGAS, taking up option to buy IFM unit
➡ Merck bets up to $1B on Pearl Bio’s ‘smart’ biologics
➡ Sensorion’s hearing loss drug reaches target in comeback story
➡ Nurix Therapeutics gets BTK degrader back on track after FDA lifts hold
➡ AstraZeneca to buy Amolyt Pharma for $1.05bn to boost rare-disease portfolio
➡ Shares in Spanish drugmaker Grifols tumble on Fitch, S&P downgrades
➡ AstraZeneca plans £650 million investment in UK
➡ Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
➡ Lexaria Bioscience Corp. announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately.
➡ Precisio Biotix Therapeutics (“Precisio”) today announced it has entered into an agreement with Mayo Clinic.
➡ Aptar Pharma today announced the next phase of its global capacity expansion plan in North America, at its Aptar Congers, New York site.
➡ Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders
➡ Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
➡ Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence -powered approaches with applications in precision oncology drug research and development.
➡ Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced the closing of a CHF 2.8 million extension to its seed financing.
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
➡ Basecamp Research Launches BaseFold: A Breakthrough in 3D Protein Structure Prediction of Large, Complex Protein Structures
➡ Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced plans to open a new office in London’s vibrant King’s Cross neighbourhood.
————————————————-
Newton Colmore is a specialist provider of executive search and talent solutions to the medical devices and biotechnology sectors.
We have been helping our clients find the experts they need to develop ground-breaking products, therapeutics, and services since 2015.
#medicaldevices #biotechnology #lifesciences #therapeutics #technology #business #drugdiscovery